Priothera Announces First Patients Enrolled in Pivotal MO-TRANS Global Phase IIb/III Study with Mocravimod as an Adjunctive and Maintenance Therapy for Patients with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)

Priothera announced that the first patients have been enrolled in the pivotal MO-TRANS global Phase IIb/III study evaluating mocravimod in AML patients undergoing allogeneic hematopoietic cell transplant.
[Priothera ( Cision US Inc.)]
Press Release

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News